MedDataX Logo

Microbial Community Composition and Metabolism in Cystic Fibrosis

NCT ID: NCT00954018

Last Updated: 2023-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Study Completion Date

2017-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Scientist have begun to realize that many types of bacteria often live together as a complex community, and the investigators wish to apply that idea to the bacteria in the respiratory system of people with Cystic Fibrosis (CF). It is possible that the survival of the many millions of bacteria in the CF lung depends on the production of special chemicals that might be made only by very few types of bacteria. If that is true, medicines that interfere with those chemicals could treat the lung infections that cause trouble for nearly all people with CF. The investigators wish to study the production of several potentially critical chemicals by the respiratory bacteria and to examine the effect of those chemicals on the makeup of the entire community of bacteria. To detect all the bacteria in that community, the investigators will use new methods that use bacterial genetic information and can detect hundreds of different types of bacteria in respiratory samples of individual CF patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs

NCT00590330

Cystic Fibrosis
COMPLETED

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

NCT00977158

Cystic Fibrosis
WITHDRAWN

Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis

NCT01661491

Cystic Fibrosis
COMPLETED

The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective

NCT01306279

Cystic Fibrosis
COMPLETED

Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations

NCT04354038

Cystic Fibrosis
ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cystic Fibrosis patient during outpatient clinic visit

No interventions assigned to this group

Cystic Fibrosis patients during hospitalization

No interventions assigned to this group

CF patients about to have sinus surgery and bronchoscopy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed diagnosis of Cystic Fibrosis
* 2 to 55 years of age

Exclusion Criteria

* None
Minimum Eligible Age

2 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts Institute of Technology

OTHER

Sponsor Role collaborator

Harvard Medical School (HMS and HSDM)

OTHER

Sponsor Role collaborator

Boston Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thomas Martin

Assistant Professor of Pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hosptital, Boston

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09-04-018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients
NCT04735679 UNKNOWN
Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis
NCT04024423 COMPLETED
Clinical Course and Changes in the Respiratory Microbiota Based on Antibiotic Treatment in Patients With Cystic Fibrosis
NCT01693965 COMPLETED NA
Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
NCT05686837 ENROLLING_BY_INVITATION
Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of People With Cystic Fibrosis
NCT00531531 COMPLETED
Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients
NCT00004296 COMPLETED
The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults
NCT01238081 COMPLETED
Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome
NCT05982795 RECRUITING
Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis
NCT03335202 UNKNOWN
Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
NCT03801993 COMPLETED
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
NCT04341532 RECRUITING
Costimulatory Molecules as Biomarkers in Cystic Fibrosis
NCT01353950 COMPLETED
Home Monitoring to Predict Exacerbation in Cystic Fibrosis
NCT02416375 COMPLETED
Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
NCT02547116 WITHDRAWN PHASE4
Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis
NCT00577252 COMPLETED
Airway Microbiome of Cystic Fibrosis Patients
NCT06057558 ACTIVE_NOT_RECRUITING NA
Fitness, Body Composition, Physical Activity and Sleep Patterns in People With Cystic Fibrosis on Modulator Therapy.
NCT05857709 UNKNOWN
Evaluating Sensations of Breathlessness in Patients With Cystic Fibrosis
NCT01799642 COMPLETED
The Role of Bacteria and Genetic Variations in Cystic Fibrosis
NCT00043225 COMPLETED
Near Patient Microbial Testing in Cystic Fibrosis
NCT01877707 COMPLETED NA
Tissue Collection From People With Cystic Fibrosis
NCT00015756 COMPLETED
A Study to Investigate Cystic Fibrosis Pulmonary Exacerbations and the Lung Microbiome
NCT05088447 TERMINATED
Breath Condensate Study in Patients With Cystic Fibrosis.
NCT02056132 COMPLETED
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
NCT03312075 UNKNOWN
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
NCT00850551 COMPLETED NA